v3.26.1
Segment Reporting (Details)
$ in Thousands
3 Months Ended
Mar. 31, 2026
USD ($)
segment
Mar. 31, 2025
USD ($)
Segment Reporting    
Number of operating segments | segment 1  
Number of reportable segments | segment 1  
Revenue $ 10,785 $ 10,698
Cost of product revenue 1,329 1,262
Research & Development    
Stock-based compensation 15,582 10,456
Depreciation 1,283 981
Interest income 6,050 3,826
Interest expense (2,777) (2,984)
Net loss (88,612) (64,053)
Single reportable segment    
Segment Reporting    
Revenue 10,785 10,698
Cost of product revenue 1,329 1,262
Research & Development    
AXPAXLI 42,460 24,647
Direct program expenses, Other clinical and preclinical programs 758 889
Unallocated expenses, Personnel costs 12,976 8,983
Unallocated expenses, All other costs 1,809 3,255
Selling & Marketing 14,075 12,817
General & Administrative 11,606 9,661
Facilities 2,270 1,664
Stock-based compensation 15,582 10,456
Depreciation 1,260 981
Interest income 6,050 3,826
Interest expense (2,777) (2,984)
Other non-operating items 1,455 (978)
Net loss $ (88,612) $ (64,053)